Benjamin P. Haynes

Medicine · Health Sciences

12h-index664citations35works0.52yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(19), Lung Cancer Treatments and Mutations(17), Advanced Breast Cancer Therapies(13), Estrogen and related hormone effects(6), Pharmacogenetics and Drug Metabolism(5)

Publications35 total

125P Development and evaluation of a highly sensitive qPCR assay for ESR1 mutation monitoring
ESMO Open·2025Open Access
420P An exosome-based ESR1 monitoring RT-qPCR kit that rapidly and accurately detects acquired resistance variants at ≤ 0.1% frequency in liquid biopsy samples
Annals of Oncology·2024· 1 citedOpen Access
Supplementary Table 2 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Table 4 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Table and Figure Legends from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Table 3 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Data from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Table 1 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Figure 1 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Data from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Figure 2 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Figure 3 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Figure 1 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Table and Figure Legends from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Table 4 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Figure 3 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Table 1 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Table 3 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Figure 2 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
Supplementary Table 2 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
2023Open Access
page 1 of 2Next →

Frequent Co-authors

Mitch Dowsett(25), Alexandra Léary(19), Abigail Evans(19), Stephen Johnston(19), Roger A’Hern(19), Judith M. Bliss(19), Rashmita Sahoo(19), Simone Detre(19), Margaret Hills(19), Catherine Harper‐Wynne(19), Nigel Bundred(19), Gill Coombes(19), Ian Smith(19), Michael Jarman(5), Gerard A. Potter(4), S. Elaine Barrie(3), Phyllis M. Goddard(2), R. Charles Coombes(2), Leslie J. Griggs(2), Sarah Statt(2)